S3NS Announces SecNumCloud Qualification for PREMI3NS, its Trusted Cloud Offering
19.12.2025 08:00:00 EET | Business Wire | Press release
S3NS, a subsidiary of Thales in partnership with Google Cloud, today announced that PREMI3NS, its "Trusted Cloud" (Cloud de confiance) offering, has received the SecNumCloud 3.2 qualification delivered by the French National Agency for the Security of Information Systems (ANSSI). Meeting SecNumCloud 3.2’s protection and resilience requirements, which are known as the most demanding ones in France and Europe, it offers immunity from non-European extraterritorial laws.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218817208/en/
ANSSI delivered the SecNumCloud 3.2 qualification for S3NS’ PREMI3NS offering, meeting all its requirements and passing all three milestones of the qualification process.
With PREMI3NS, S3NS now offers businesses and public sector organizations the most extensive cloud service among the offerings that have received the SecNumCloud 3.2 qualification. PREMI3NS integrates the most advanced IaaS and PaaS technology from Google Cloud.
" The SecNumCloud 3.2 qualification is the result of the unparalleled collaboration between two cloud and cybersecurity leaders. It opens new opportunities for the French and European markets. Never has a SecNumCloud 3.2 - certified cloud offering included such a wide range of managed services. PREMI3NS will enable its customers to innovate, optimize, and transform with utmost confidence and security with their most sensitive applications. As a matter of fact, Thales group has chosen S3NS for its own IT and its sensitive engineering." said Christophe Salomon, Deputy CEO, Secure Information and Communication Systems, Thales.
The SecNumCloud 3.2 qualification results from the original strategic partnership between Thales and Google Cloud and the creation of S3NS in 2022. It is the assertion of their combined ambition to offer an unparalleled solution on the market and is now available to all public and private organizations. With this qualification, S3NS, a company operating under French law and fully controlled by Thales, fulfills its commitment to deploying the most feature-rich cloud offering meeting the SecNumCloud 3.2 requirements on the market within three years of its creation.
PREMI3NS is operated and managed exclusively by S3NS employees in data centers located in France. All cloud technologies and their updates are quarantined, analyzed and then validated by S3NS before the company manages them in its dedicated infrastructure.
The SecNumCloud 3.2 framework is the most demanding standard for cloud security in Europe. France is currently the only country to require its public sector organizations to comply with its requirements when managing sensitive data, as the government commits to guaranteeing French citizens the optimal protection of their data.
Organizations are already choosing S3NS
PREMI3NS, now SecNumCloud-qualified, has been accessible for several months as part of S3NS’ “early adopters” program and tested by about thirty pioneering customers. S3NS is currently supporting insurance companies (MGEN, Matmut, AGPM), companies from the manufacturing industry (Thales, Birdz, a subsidiary of Veolia), the financial sector (Qonto, BConnect) and services (Club Med) as they progressively migrate to the "Trusted Cloud" and leverage the combined expertise of Thales and Google Cloud. EDF selected S3NS for the storage, processing, and valorization of the Group's strategic data, and Thales is already using PREMI3NS for its internal information system and its engineering.
The broadest range of cloud services with the SecNumCloud qualification on the market
PREMI3NS offers a large portfolio of IaaS, PaaS, and CaaS services, allowing organizations to operate their most sensitive applications in a high-performance and trusted environment. The offering revolves around fundamental and proven Google Cloud technological components, such as Compute Engine for virtual machine management, Cloud Storage for data storage, and Cloud SQL for relational databases. This robust foundation provides access to all the capacity, innovation, and robustness of the cloud through advanced managed services, including Google Kubernetes Engine for containerization, BigQuery for the market-leading, serverless, and highly scalable data warehouse preparing for an easy transition to AI, as well as cutting-edge solutions for network and interconnection management.
This extensive service portfolio will continue to grow in the coming months with S3NS notably preparing the integration of generative artificial intelligence solutions, and reaffirming its commitment to providing its customers with constant access to the most innovative technologies, within a trusted framework.
About S3NS
An alliance between Thales, a global leader in data protection and cybersecurity, and Google Cloud, a global leader in cloud technologies, S3NS offers public institutions and private companies, concerned about further protecting their most sensitive data, highly secure public cloud offerings to operate their transition to the trusted cloud, meeting the criteria of the ANSSI SecNumCloud framework. S3NS is a company under French law entirely controlled by Thales.
To know more
S3NS |Thales x Google Cloud targeting a trusted cloud
S3NS Cloud de Confiance enters General Availability
View source version on businesswire.com: https://www.businesswire.com/news/home/20251218817208/en/
Contacts
MEDIA
Media relations (Thales, S3NS)
Marion Bonnet
marion.bonnet@thalesgroup.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom